John Kuruvilla, MD, on the Implications of the Phase III KEYNOTE-204 Study

Results from the study indicated that pembrolizumab (Keytruda) was superior to brentuximab vedotin (Adcetris) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: John Kuruvilla, MD Source Type: news